Drug Trial Radar · NCT06449586
CMV-specific T Cell Immunity Test Indicated Prophylaxis of Letermovir After All-HSCT
Last checked: Nov 20, 2026Latest source record: Dec 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
250
Planned (sponsor's estimate)
Start
Jul 1, 2024
Primary completion
Jun 1, 2026
Study completion Jun 1, 2026
Sponsor
- Lead sponsor
- Ruijin HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 10, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the efficacy of CMV-specific T cell immunity test in prolonged usage of letermovir for avoiding late-onset csCMVi after all-HSCT.
Conditions
- Hematologic Malignancy
Interventions
LetermovirDrug
letermovir stops when CMI\>1.5
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of late-onset clinical significant CMV (cs-CMV) infectionTime frame: through study completion, an average of 1 year
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Ruijin Hospital, Shanghai JiaoTong University School of Medicine
Shanghai, China
Shanghai Liquan Hospital
Shanghai, China
Tongji Hospital of Huazhong University of Science and Technology, Wuhan
Wuhan, Hubei, China
Ruijin Hospital of Shanghai Jiaotong University
Shanghai, Shanghai Municipality, China
The First Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.